May 8, 2018 / 11:09 AM / 5 months ago

BRIEF-Aralez Pharmaceuticals Announces Discontinuation Of U.S. Commercial Operations, With Reductions In Operating Expenses

May 8 (Reuters) - Aralez Pharmaceuticals Inc:

* ARALEZ ANNOUNCES NEW STRATEGIC DIRECTION

* ARALEZ PHARMACEUTICALS INC - DISCONTINUATION OF U.S. COMMERCIAL OPERATIONS, WITH SIGNIFICANT REDUCTIONS IN OPERATING EXPENSES

* ARALEZ PHARMACEUTICALS INC - FOCUS ON CANADIAN OPERATIONS, SUPPORTED BY TOPROL-XL FRANCHISE REVENUES AND VIMOVO ROYALTIES

* ARALEZ PHARMACEUTICALS INC - CONCLUDED THAT MOMENTUM FROM ZONTIVITY ALONE IS INSUFFICIENT TO SUSTAIN U.S. COMMERCIAL INFRASTRUCTURE

* ARALEZ PHARMACEUTICALS INC - ACTIVELY EXPLORING STRATEGIC ALTERNATIVES FOR BUSINESS

* ARALEZ PHARMACEUTICALS INC - ARALEZ CANADA WILL FOCUS ON DRIVING ORGANIC GROWTH IN CANADA WITH BLEXTEN AND CAMBIA

* ARALEZ PHARMACEUTICALS INC - ARALEZ EXPECTS CASH OPERATING EXPENSES WILL BE REDUCED TO ABOUT $25 MILLION ON AN ANNUALIZED BASIS

* ARALEZ PHARMACEUTICALS INC - STRATEGIC ALTERNATIVES INCLUDE ACTIVE DISCUSSIONS TO DIVEST U.S. RIGHTS TO YOSPRALA, FIBRICOR AND BEZALIP SR

* ARALEZ PHARMACEUTICALS INC - COMPANY CAUTIONS THAT IT HAS VERY RECENTLY EXPERIENCED INCREASED GENERIC COMPETITION WITH RESPECT TO TOPROL-XL FRANCHISE

* ARALEZ PHARMACEUTICALS INC - STRATEGIC ALTERNTIVES ALSO INCLUDE BROADER STRATEGIC AND REFINANCING ALTERNATIVES FOR ITS BUSINESS

* ARALEZ PHARMACEUTICALS INC - EVALUATING MARKET DYNAMICS, EXPLORING OPPORTUNITIES TO MITIGATE RISK INVOLVED WITH TOPROL-XL FRANCHISE COMPETITION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below